We Manufacture Products That Change Lives™
Life changing perinatal tissue allografts based on our proprietary BioREtain® process.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are manufactured using our proprietary BioRetain® processing method that preserves the quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are processed using our proprietary BioRetain® processing method that preserves the biologic quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Why Choose Us
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
Our allografts are processed utilizing our proprietary BioRetain® method, which focuses on preserving the tissue’s endogenous biological properties while maintaining the structure and matrix found in fresh perinatal tissue.
BioStem is committed to improving patients’ quality of life through scientific innovation and strict adherence to our quality system.
Latest News
-
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor Strengthening balance sheet on path to Nasdaq uplisting
POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds…
Subscribe to our Newsletter
To stay up to date on all of our news, products, and achievements, please subscribe to our newsletter.
